Transferrin Serves As a Mediator to Deliver Organometallic Ruthenium(II) Anticancer Complexes into Cells
Authors:
- 15 April 2013
- journal article
- research article
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 52 (9) , 5328-5338
Abstract
We report herein a systematic study on interactions of organometallic ruthenium(II) anticancer complex [(η6-arene)Ru(en)Cl]+ (arene = p-cymene (1) or biphenyl (2), en = ethylenediamine) with human transferrin (hTf) and the effects of the hTf-ligation on the bioavailability of these complexes with cisplatin as a reference. Incubated with a 5-fold excess of complex 1, 2, or cisplatin, 1 mol of diferric hTf (holo-hTf) attached 0.62 mol of 1, 1.01 mol of 2, or 2.14 mol of cisplatin. Mass spectrometry revealed that both ruthenium complexes coordinated to N-donors His242, His273, His578, and His606, whereas cisplatin bound to O donors Tyr136 and Tyr317 and S-donor Met256 in addition to His273 and His578 on the surface of both apo- and holo-hTf. Moreover, cisplatin could bind to Thr457 within the C-lobe iron binding cleft of apo-hTf. Neither ruthenium nor platinum binding interfered with the recognition of holo-hTf by the transferrin receptor (TfR). The ruthenated/platinated holo-hTf complexes could be internalized via TfR-mediated endocytosis at a similar rate to that of holo-hTf itself. Moreover, the binding to holo-hTf well preserved the bioavailability of the ruthenium complexes, and the hTf-bound 1 and 2 showed a similar cytotoxicity toward the human breast cancer cell line MCF-7 to those of the complexes themselves. However, the conjugation with holo-hTf significantly reduced the cellular uptake of cisplatin and the amount of platinated DNA adducts formed intracellularly, leading to dramatic reduction of cisplatin cytotoxicity toward MCF-7. These findings suggest that hTf can serve as a mediator for the targeting delivery of Ru(arene) anticancer complexes while deactivating cisplatin.Keywords
This publication has 55 references indexed in Scilit:
- Iron and bismuth bound human serum transferrin reveals a partially-opened conformation in the N-lobeScientific Reports, 2012
- Antitumour metal compounds: more than theme and variationsDalton Transactions, 2007
- Gallium-induced cell death in lymphoma: role of transferrin receptor cycling, involvement of Bax and the mitochondria, and effects of proteasome inhibitionMolecular Cancer Therapeutics, 2006
- Transferrin: structure, function and potential therapeutic actionsDrug Discovery Today, 2005
- Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopyJournal of Analytical Atomic Spectrometry, 2003
- Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis PathwayPharmacological Reviews, 2002
- A comparative study of aluminum(III), gallium(III), indium(III), and thallium(III) binding to human serum transferrinCoordination Chemistry Reviews, 2002
- Transferrin as a Metal Ion MediatorChemical Reviews, 1999
- Structure of recombinant human lactoferrin expressed in Aspergillus awamoriActa Crystallographica Section D Structural Biology, 1999
- Structure of Human Apolactoferrin at 2.0 Å Resolution. Refinement and Analysis of Ligand-Induced Conformational ChangeActa Crystallographica Section D Structural Biology, 1998